CMC Icos Biologics, the Bothell, WA-based contract manufacturer of biotech drugs, said today it has signed a deal to manufacture an experimental drug for acute lung injury. CMC will make IC14, an antibody drug, for Brisbane, Australia-based Implicit Bioscience. The treatment, which is scheduled to enter Phase II trials next year, was previously tested in 150 patients by Icos for its potential against inflammatory diseases.
Author: Luke Timmerman
Luke is an award-winning journalist specializing in life sciences. He has served as national biotechnology editor for Xconomy and national biotechnology reporter for Bloomberg News. Luke got started covering life sciences at The Seattle Times, where he was the lead reporter on an investigation of doctors who leaked confidential information about clinical trials to investors. The story won the Scripps Howard National Journalism Award and several other national prizes. Luke holds a bachelor’s degree in journalism from the University of Wisconsin-Madison, and during the 2005-2006 academic year, he was a Knight Science Journalism Fellow at MIT.
View all posts by Luke Timmerman
